Clinical and immunological impact of JAK inhibition in concurrent Down Syndrome and STAT1 gain of function
Rattachement africain : es. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: Down syndrome (DS) and STAT1 gain-of-function (GOF) share clinical and molecular features, including persistent inflammation. We aim to investigate whether the coexistence of DS and a STAT1 GOF mutation in a patient synergistically enhance interferon (IFN) signaling and exacerbate inflammatory responses, posing additional management challenges. Methods: Two patients (P1 and P2) were studied: P1, with DS and a heterozygous p.P326S STAT1 variant, and P2, with the STAT1 p.P326S variant only. Individuals with isolated DS or STAT1 GOF served as controls. IFN receptor subunits (IFNγR1/R2 and IFNαR1/R2) and responses to IFNα/γ stimulation were analyzed using flow cytometry and RT-PCR. Whole blood type-I IFN signature and serum cytokines were evaluated using NanoString and Luminex assays, respectively. Results: P1 experienced recurrent infections, chronic mucocutaneous candidiasis, interstitial pneumonitis, and pulmonary hypertension. P2 presented with esophageal candidiasis, dysphagia, and stenosis. The p.P326S variant led to increased STAT1/pSTAT1 levels in response to IFNα/γ. Both patients showed significant clinical improvement with the Janus kinase (JAK) inhibitor ruxolitinib. However, in P1, key biomarkers (STAT1 levels, IFN signature, and cytokines such as TNFα and IL-6) remained altered, indicating persistent inflammation despite clinical improvement. Conclusion: This first report of a STAT1 GOF variant in DS provides a unique ”experiment of nature,” offering insights into the interplay between trisomy 21 and STAT1-mediated immune dysregulation. Although treatment with ruxolitinib demonstrated clinical benefits, the persistent inflammation observed in P1 highlights the need for further strategies to achieve complete immune resolution. These findings emphasize the importance of comprehensive genetic and immunologic assessments in individuals with DS, particularly when immune dysfunction is suspected.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Clinical and immunological impact of JAK inhibition in concurrent Down Syndrome and STAT1 gain of function
- Date Crossref
- 17/04/2025
- Éditeur
- Wiley
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.